This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Cyclin B1 (CCNB1)	<p>Studies in mice and human plasma samples suggest that CCNB1-based vaccines could help treat cancer. The tumor antigen CCNB1 is overexpressed in many cancers but only transiently expressed in normal cells. Lymphoma mouse models that received <i>CCNB1</i> DNA vaccination were more frequently tumor free and had lower tumor volumes than unvaccinated controls ($p=0.0013$ and $p<0.0001$, respectively). The vaccinated mice had detectable anti-CCNB1 antibodies and antigen-specific T cells. Phase I/II testing of a CCNB1-based vaccine in patients with stage IB and II lung cancer will begin this year.</p> <p>SciBX 2(31); doi:10.1038/scibx.2009.1203 Published online Aug. 13, 2009</p>	Patented; licensing status undisclosed	<p>Vella, L. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Aug. 3, 2009; doi:10.1073/pnas.0903225106</p> <p>Contact: Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, Pa. e-mail: ojfinn@pitt.edu</p>